<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In order to establish diagnostic criteria for hypocellular <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>), we have reviewed 32 cases selected on the basis of hypothetical 40% or less cellularity, by focusing on <z:mp ids='MP_0000002'>morphology</z:mp>, immunophenotype, karyotype and response to low dose Ara-C (LDAC) regimen and compared them with 40 cases of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and 66 cases of overt <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:hpo ids='HP_0003674'>onset</z:hpo> age ranged from 44 to 75 years (median 67 years) </plain></SENT>
<SENT sid="2" pm="."><plain>Bone marrow (BM) cellularity ranged from 12.4 to 39.8% (mean 29.8%) in <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>, being significantly lower than in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (mean 80.7%) or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (mean 86.4%) (P &lt; 0.001) </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> reviewed cases characteristically showed smoldering clinical course, bi- or <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> with rare leukemic blasts in the peripheral blood (PB), proliferation of type I leukemic blasts in the BM and markedly reduced background hematopoietic cells with some dysplastic changes in 12/32 cases (37.50/6) </plain></SENT>
<SENT sid="4" pm="."><plain>Blast percentage (blast %) in the BM ranged from 38.2 to 93.7% (mean 57.3%) in <z:hpo ids='HP_0000001'>all</z:hpo> nucleated cells (ANC) </plain></SENT>
<SENT sid="5" pm="."><plain>Although a considerable number of cases had blasts with negative or very low myeloperoxidase activity, immunophenotyping revealed that the leukemic blasts in <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> had only myeloid markers </plain></SENT>
<SENT sid="6" pm="."><plain>Karyotyping revealed non-random chromosome abnormalities in 30% of cases analyzed, which were considerably different from those seen in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>With LDAC regimen, a significantly higher CR rate (13/20 cases: 65.0%) was gained in <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> than in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t (0%) and overt <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in the elderly cases (27.3%) (P &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>In CR, most cases showed recovery to normocellular BM with an apparent normalization of PB parameters </plain></SENT>
<SENT sid="9" pm="."><plain>However, 12 CR cases relapsed 4-12 months later; most of which again showed hypocellular BM </plain></SENT>
<SENT sid="10" pm="."><plain>These results indicate that <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> is a distinct subtype of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> characterized by slow but distinct proliferation of immature myeloid blasts and by unique hematological features distinct from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or overt <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in the elderly </plain></SENT>
<SENT sid="11" pm="."><plain>We propose the following diagnostic criteria: (1) <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> with rare appearance of blasts in PB; (2) less than 40% BM hypocellularity; (3) more than 30% blasts in BM-ANC; and (4) myeloid phenotypes of leukemic blasts by MPO staining and/or immunophenotyping </plain></SENT>
</text></document>